豚流行性脳炎不活化ワクチンの世界市場2023-2029:マウス脳不活化ワクチン、細胞培養不活化ワクチン、細胞培養弱毒化生ワクチン、遺伝子組み換え生弱毒化ワクチン

• 英文タイトル:Global Swine Epidemic Encephalitis Inactivated Vaccine Market Growth 2023-2029

Global Swine Epidemic Encephalitis Inactivated Vaccine Market Growth 2023-2029「豚流行性脳炎不活化ワクチンの世界市場2023-2029:マウス脳不活化ワクチン、細胞培養不活化ワクチン、細胞培養弱毒化生ワクチン、遺伝子組み換え生弱毒化ワクチン」(市場規模、市場予測)調査レポートです。• レポートコード:MRCLP3DB3185
• 出版社/出版日:LP Information / 2023年12月
• レポート形態:英文、PDF、119ページ
• 納品方法:Eメール(納期:2-3営業日)
• 産業分類:医薬品&医療
• 販売価格(消費税別)
  Single User¥541,680 (USD3,660)▷ お問い合わせ
  Corporate User¥1,083,360 (USD7,320)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
LPインフォメーション社の最新調査レポート「豚流行性脳炎不活化ワクチンの世界市場」は、過去の販売実績から2022年の世界の豚流行性脳炎不活化ワクチンの総販売量を検討し、2023年から2029年の予測される豚流行性脳炎不活化ワクチンの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の豚流行性脳炎不活化ワクチンの市場規模を掲載し、XXX百万米ドル規模の世界の豚流行性脳炎不活化ワクチン市場の詳細な分析を提供します。本インサイトレポートは、世界の豚流行性脳炎不活化ワクチン業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。

また、本資料では、加速する世界の豚流行性脳炎不活化ワクチン市場における各社の独自のポジションをより深く理解するために、豚流行性脳炎不活化ワクチン製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の豚流行性脳炎不活化ワクチン市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。豚流行性脳炎不活化ワクチンの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000%と予測されています。豚流行性脳炎不活化ワクチンの中国市場は、2023年から2029年までの年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。豚流行性脳炎不活化ワクチンの欧州市場は、2023年から2029年にかけて年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

豚流行性脳炎不活化ワクチンの世界主要メーカーとしては、KM Biologics、 Zoetis Animal Health、 Boehringer-Ingelheim、 Eurovet、 Hipra、 China Animal Husbandry Industry、 Inyu Bio-technology、 TECON、 SPAH、 Chongqing Auleon Biologicals、 Wuhan Keqian Biology、 Hunan Sinoland Bio-Pharmaceutical、 MERRY、 Shanghai Hile Bio-Technology、 Guangdong Winsun Bio Pharmaceutical、 Jinhe Biotechnologyなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000%のシェアを占めています。

本調査資料では、製品タイプ、用途、主要メーカー、主要地域、国別の豚流行性脳炎不活化ワクチン市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

本調査では豚流行性脳炎不活化ワクチン市場をセグメンテーションし、種類別 (マウス脳不活化ワクチン、細胞培養不活化ワクチン、細胞培養弱毒化生ワクチン、遺伝子組み換え生弱毒化ワクチン)、用途別 (子豚、成豚)、および地域別 (アジア太平洋、南北アメリカ、欧州、および中東・アフリカ) の市場規模を予測しています。

・種類別区分:マウス脳不活化ワクチン、細胞培養不活化ワクチン、細胞培養弱毒化生ワクチン、遺伝子組み換え生弱毒化ワクチン

・用途別区分:子豚、成豚

・地域別区分
南北アメリカ(アメリカ、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
欧州(ドイツ、フランス、イギリス、イタリア、ロシア)
中東・アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

【本レポートで扱う主な質問】

・世界の豚流行性脳炎不活化ワクチン市場の10年間の市場状況・展望は?
・世界および地域別に見た豚流行性脳炎不活化ワクチン市場成長の要因は何か?
・豚流行性脳炎不活化ワクチンの市場機会はエンドマーケットの規模によってどのように変化するのか?
・豚流行性脳炎不活化ワクチンのタイプ別、用途別の内訳は?
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は?

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:豚流行性脳炎不活化ワクチンの年間販売量2018-2029、地域別現状・将来分析
・豚流行性脳炎不活化ワクチンの種類別セグメント:マウス脳不活化ワクチン、細胞培養不活化ワクチン、細胞培養弱毒化生ワクチン、遺伝子組み換え生弱毒化ワクチン
・豚流行性脳炎不活化ワクチンの種類別販売量:2018-2023年の販売量、売上、市場シェア、販売価格
・豚流行性脳炎不活化ワクチンの用途別セグメント:子豚、成豚
・豚流行性脳炎不活化ワクチンの用途別販売量:2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の豚流行性脳炎不活化ワクチン市場
・企業別のグローバル豚流行性脳炎不活化ワクチン市場データ:2018-2023年の年間販売量、市場シェア
・企業別の豚流行性脳炎不活化ワクチンの年間売上:2018-2023年の売上、市場シェア
・企業別の豚流行性脳炎不活化ワクチン販売価格
・主要企業の豚流行性脳炎不活化ワクチン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

豚流行性脳炎不活化ワクチンの地域別レビュー
・地域別の豚流行性脳炎不活化ワクチン市場規模2018-2023:年間販売量、売上
・主要国別の豚流行性脳炎不活化ワクチン市場規模2018-2023:年間販売量、売上
・南北アメリカの豚流行性脳炎不活化ワクチン販売の成長
・アジア太平洋の豚流行性脳炎不活化ワクチン販売の成長
・欧州の豚流行性脳炎不活化ワクチン販売の成長
・中東・アフリカの豚流行性脳炎不活化ワクチン販売の成長

南北アメリカ市場
・南北アメリカの国別の豚流行性脳炎不活化ワクチン販売量、売上(2018-2023)
・南北アメリカの豚流行性脳炎不活化ワクチンの種類別販売量
・南北アメリカの豚流行性脳炎不活化ワクチンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の豚流行性脳炎不活化ワクチン販売量、売上(2018-2023)
・アジア太平洋の豚流行性脳炎不活化ワクチンの種類別販売量
・アジア太平洋の豚流行性脳炎不活化ワクチンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

欧州市場
・欧州の国別の豚流行性脳炎不活化ワクチン販売量、売上(2018-2023)
・欧州の豚流行性脳炎不活化ワクチンの種類別販売量
・欧州の豚流行性脳炎不活化ワクチンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の豚流行性脳炎不活化ワクチン販売量、売上(2018-2023)
・中東・アフリカの豚流行性脳炎不活化ワクチンの種類別販売量
・中東・アフリカの豚流行性脳炎不活化ワクチンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・豚流行性脳炎不活化ワクチンの製造コスト構造分析
・豚流行性脳炎不活化ワクチンの製造プロセス分析
・豚流行性脳炎不活化ワクチンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・豚流行性脳炎不活化ワクチンの主要なグローバル販売業者
・豚流行性脳炎不活化ワクチンの主要なグローバル顧客

地域別の豚流行性脳炎不活化ワクチン市場予測レビュー
・地域別の豚流行性脳炎不活化ワクチン市場規模予測(2024-2029)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・欧州の国別予測
・豚流行性脳炎不活化ワクチンの種類別市場規模予測
・豚流行性脳炎不活化ワクチンの用途別市場規模予測

主要企業分析
KM Biologics、 Zoetis Animal Health、 Boehringer-Ingelheim、 Eurovet、 Hipra、 China Animal Husbandry Industry、 Inyu Bio-technology、 TECON、 SPAH、 Chongqing Auleon Biologicals、 Wuhan Keqian Biology、 Hunan Sinoland Bio-Pharmaceutical、 MERRY、 Shanghai Hile Bio-Technology、 Guangdong Winsun Bio Pharmaceutical、 Jinhe Biotechnology
・企業情報
・豚流行性脳炎不活化ワクチン製品
・豚流行性脳炎不活化ワクチン販売量、売上、価格、粗利益(2018-2023)
・主要ビジネス概要
・最新動向

調査結果および結論

The global Swine Epidemic Encephalitis Inactivated Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Swine Epidemic Encephalitis Inactivated Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Swine Epidemic Encephalitis Inactivated Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Swine Epidemic Encephalitis Inactivated Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Swine Epidemic Encephalitis Inactivated Vaccine players cover KM Biologics, Zoetis Animal Health, Boehringer-Ingelheim, Eurovet, Hipra, China Animal Husbandry Industry, Inyu Bio-technology, TECON and SPAH, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Swine Epidemic Encephalitis Inactivated Vaccine is inoculated into the brains of mice with the porcine Japanese encephalitis virus HW1 strain, and the infected mouse brain tissue is harvested to make a suspension, which is inactivated by formaldehyde solution and emulsified with an adjuvant. For the prevention of porcine Japanese encephalitis.
LPI (LP Information)’ newest research report, the “Swine Epidemic Encephalitis Inactivated Vaccine Industry Forecast” looks at past sales and reviews total world Swine Epidemic Encephalitis Inactivated Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Swine Epidemic Encephalitis Inactivated Vaccine sales for 2023 through 2029. With Swine Epidemic Encephalitis Inactivated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Swine Epidemic Encephalitis Inactivated Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Swine Epidemic Encephalitis Inactivated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Epidemic Encephalitis Inactivated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Swine Epidemic Encephalitis Inactivated Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Epidemic Encephalitis Inactivated Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Epidemic Encephalitis Inactivated Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Swine Epidemic Encephalitis Inactivated Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Mouse Brain Inactivated Vaccine
Cell Culture Inactivated Vaccine
Cell Culture Live Attenuated Vaccine
Genetically Engineered Live Attenuated Vaccine
Segmentation by application
Piglets
Adults Pigs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
KM Biologics
Zoetis Animal Health
Boehringer-Ingelheim
Eurovet
Hipra
China Animal Husbandry Industry
Inyu Bio-technology
TECON
SPAH
Chongqing Auleon Biologicals
Wuhan Keqian Biology
Hunan Sinoland Bio-Pharmaceutical
MERRY
Shanghai Hile Bio-Technology
Guangdong Winsun Bio Pharmaceutical
Jinhe Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Swine Epidemic Encephalitis Inactivated Vaccine market?
What factors are driving Swine Epidemic Encephalitis Inactivated Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Swine Epidemic Encephalitis Inactivated Vaccine market opportunities vary by end market size?
How does Swine Epidemic Encephalitis Inactivated Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

レポート目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Swine Epidemic Encephalitis Inactivated Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Swine Epidemic Encephalitis Inactivated Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Swine Epidemic Encephalitis Inactivated Vaccine Segment by Type
2.2.1 Mouse Brain Inactivated Vaccine
2.2.2 Cell Culture Inactivated Vaccine
2.2.3 Cell Culture Live Attenuated Vaccine
2.2.4 Genetically Engineered Live Attenuated Vaccine
2.3 Swine Epidemic Encephalitis Inactivated Vaccine Sales by Type
2.3.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Swine Epidemic Encephalitis Inactivated Vaccine Sale Price by Type (2018-2023)
2.4 Swine Epidemic Encephalitis Inactivated Vaccine Segment by Application
2.4.1 Piglets
2.4.2 Adults Pigs
2.5 Swine Epidemic Encephalitis Inactivated Vaccine Sales by Application
2.5.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Swine Epidemic Encephalitis Inactivated Vaccine Sale Price by Application (2018-2023)
3 Global Swine Epidemic Encephalitis Inactivated Vaccine by Company
3.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Breakdown Data by Company
3.1.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Revenue by Company (2018-2023)
3.2.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Swine Epidemic Encephalitis Inactivated Vaccine Sale Price by Company
3.4 Key Manufacturers Swine Epidemic Encephalitis Inactivated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Swine Epidemic Encephalitis Inactivated Vaccine Product Location Distribution
3.4.2 Players Swine Epidemic Encephalitis Inactivated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Swine Epidemic Encephalitis Inactivated Vaccine by Geographic Region
4.1 World Historic Swine Epidemic Encephalitis Inactivated Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Swine Epidemic Encephalitis Inactivated Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Swine Epidemic Encephalitis Inactivated Vaccine Sales Growth
4.4 APAC Swine Epidemic Encephalitis Inactivated Vaccine Sales Growth
4.5 Europe Swine Epidemic Encephalitis Inactivated Vaccine Sales Growth
4.6 Middle East & Africa Swine Epidemic Encephalitis Inactivated Vaccine Sales Growth
5 Americas
5.1 Americas Swine Epidemic Encephalitis Inactivated Vaccine Sales by Country
5.1.1 Americas Swine Epidemic Encephalitis Inactivated Vaccine Sales by Country (2018-2023)
5.1.2 Americas Swine Epidemic Encephalitis Inactivated Vaccine Revenue by Country (2018-2023)
5.2 Americas Swine Epidemic Encephalitis Inactivated Vaccine Sales by Type
5.3 Americas Swine Epidemic Encephalitis Inactivated Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Swine Epidemic Encephalitis Inactivated Vaccine Sales by Region
6.1.1 APAC Swine Epidemic Encephalitis Inactivated Vaccine Sales by Region (2018-2023)
6.1.2 APAC Swine Epidemic Encephalitis Inactivated Vaccine Revenue by Region (2018-2023)
6.2 APAC Swine Epidemic Encephalitis Inactivated Vaccine Sales by Type
6.3 APAC Swine Epidemic Encephalitis Inactivated Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Swine Epidemic Encephalitis Inactivated Vaccine by Country
7.1.1 Europe Swine Epidemic Encephalitis Inactivated Vaccine Sales by Country (2018-2023)
7.1.2 Europe Swine Epidemic Encephalitis Inactivated Vaccine Revenue by Country (2018-2023)
7.2 Europe Swine Epidemic Encephalitis Inactivated Vaccine Sales by Type
7.3 Europe Swine Epidemic Encephalitis Inactivated Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Swine Epidemic Encephalitis Inactivated Vaccine by Country
8.1.1 Middle East & Africa Swine Epidemic Encephalitis Inactivated Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Swine Epidemic Encephalitis Inactivated Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Swine Epidemic Encephalitis Inactivated Vaccine Sales by Type
8.3 Middle East & Africa Swine Epidemic Encephalitis Inactivated Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Swine Epidemic Encephalitis Inactivated Vaccine
10.3 Manufacturing Process Analysis of Swine Epidemic Encephalitis Inactivated Vaccine
10.4 Industry Chain Structure of Swine Epidemic Encephalitis Inactivated Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Swine Epidemic Encephalitis Inactivated Vaccine Distributors
11.3 Swine Epidemic Encephalitis Inactivated Vaccine Customer
12 World Forecast Review for Swine Epidemic Encephalitis Inactivated Vaccine by Geographic Region
12.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Market Size Forecast by Region
12.1.1 Global Swine Epidemic Encephalitis Inactivated Vaccine Forecast by Region (2024-2029)
12.1.2 Global Swine Epidemic Encephalitis Inactivated Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Swine Epidemic Encephalitis Inactivated Vaccine Forecast by Type
12.7 Global Swine Epidemic Encephalitis Inactivated Vaccine Forecast by Application
13 Key Players Analysis
13.1 KM Biologics
13.1.1 KM Biologics Company Information
13.1.2 KM Biologics Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.1.3 KM Biologics Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 KM Biologics Main Business Overview
13.1.5 KM Biologics Latest Developments
13.2 Zoetis Animal Health
13.2.1 Zoetis Animal Health Company Information
13.2.2 Zoetis Animal Health Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.2.3 Zoetis Animal Health Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Zoetis Animal Health Main Business Overview
13.2.5 Zoetis Animal Health Latest Developments
13.3 Boehringer-Ingelheim
13.3.1 Boehringer-Ingelheim Company Information
13.3.2 Boehringer-Ingelheim Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.3.3 Boehringer-Ingelheim Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Boehringer-Ingelheim Main Business Overview
13.3.5 Boehringer-Ingelheim Latest Developments
13.4 Eurovet
13.4.1 Eurovet Company Information
13.4.2 Eurovet Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.4.3 Eurovet Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Eurovet Main Business Overview
13.4.5 Eurovet Latest Developments
13.5 Hipra
13.5.1 Hipra Company Information
13.5.2 Hipra Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.5.3 Hipra Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Hipra Main Business Overview
13.5.5 Hipra Latest Developments
13.6 China Animal Husbandry Industry
13.6.1 China Animal Husbandry Industry Company Information
13.6.2 China Animal Husbandry Industry Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.6.3 China Animal Husbandry Industry Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 China Animal Husbandry Industry Main Business Overview
13.6.5 China Animal Husbandry Industry Latest Developments
13.7 Inyu Bio-technology
13.7.1 Inyu Bio-technology Company Information
13.7.2 Inyu Bio-technology Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.7.3 Inyu Bio-technology Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Inyu Bio-technology Main Business Overview
13.7.5 Inyu Bio-technology Latest Developments
13.8 TECON
13.8.1 TECON Company Information
13.8.2 TECON Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.8.3 TECON Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 TECON Main Business Overview
13.8.5 TECON Latest Developments
13.9 SPAH
13.9.1 SPAH Company Information
13.9.2 SPAH Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.9.3 SPAH Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 SPAH Main Business Overview
13.9.5 SPAH Latest Developments
13.10 Chongqing Auleon Biologicals
13.10.1 Chongqing Auleon Biologicals Company Information
13.10.2 Chongqing Auleon Biologicals Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.10.3 Chongqing Auleon Biologicals Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Chongqing Auleon Biologicals Main Business Overview
13.10.5 Chongqing Auleon Biologicals Latest Developments
13.11 Wuhan Keqian Biology
13.11.1 Wuhan Keqian Biology Company Information
13.11.2 Wuhan Keqian Biology Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.11.3 Wuhan Keqian Biology Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Wuhan Keqian Biology Main Business Overview
13.11.5 Wuhan Keqian Biology Latest Developments
13.12 Hunan Sinoland Bio-Pharmaceutical
13.12.1 Hunan Sinoland Bio-Pharmaceutical Company Information
13.12.2 Hunan Sinoland Bio-Pharmaceutical Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.12.3 Hunan Sinoland Bio-Pharmaceutical Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Hunan Sinoland Bio-Pharmaceutical Main Business Overview
13.12.5 Hunan Sinoland Bio-Pharmaceutical Latest Developments
13.13 MERRY
13.13.1 MERRY Company Information
13.13.2 MERRY Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.13.3 MERRY Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 MERRY Main Business Overview
13.13.5 MERRY Latest Developments
13.14 Shanghai Hile Bio-Technology
13.14.1 Shanghai Hile Bio-Technology Company Information
13.14.2 Shanghai Hile Bio-Technology Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.14.3 Shanghai Hile Bio-Technology Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Shanghai Hile Bio-Technology Main Business Overview
13.14.5 Shanghai Hile Bio-Technology Latest Developments
13.15 Guangdong Winsun Bio Pharmaceutical
13.15.1 Guangdong Winsun Bio Pharmaceutical Company Information
13.15.2 Guangdong Winsun Bio Pharmaceutical Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.15.3 Guangdong Winsun Bio Pharmaceutical Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Guangdong Winsun Bio Pharmaceutical Main Business Overview
13.15.5 Guangdong Winsun Bio Pharmaceutical Latest Developments
13.16 Jinhe Biotechnology
13.16.1 Jinhe Biotechnology Company Information
13.16.2 Jinhe Biotechnology Swine Epidemic Encephalitis Inactivated Vaccine Product Portfolios and Specifications
13.16.3 Jinhe Biotechnology Swine Epidemic Encephalitis Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Jinhe Biotechnology Main Business Overview
13.16.5 Jinhe Biotechnology Latest Developments
14 Research Findings and Conclusion




• 英文レポート名:Global Swine Epidemic Encephalitis Inactivated Vaccine Market Growth 2023-2029
• 日本語訳:豚流行性脳炎不活化ワクチンの世界市場2023-2029:マウス脳不活化ワクチン、細胞培養不活化ワクチン、細胞培養弱毒化生ワクチン、遺伝子組み換え生弱毒化ワクチン
• レポートコード:MRCLP3DB3185お問い合わせ(見積依頼・ご注文・質問)